Food and Drug Administration Transparency Task Force; Reopening of Comment Period, 41711-41712 [E9-19778]

Download as PDF Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices Management (HFA–710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, Daniel.Gittleson@fda.hhs.gov, 301–796– 5156. SUPPLEMENTARY INFORMATION: In the Federal Register of May 21, 2009 (74 FR 23865), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0186. The approval expires on July 31, 2012. A copy of the supporting statement for this information collection is available on the Internet at https://www.reginfo.gov/ public/do/PRAMain. Dated: August 11, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. 09–19785 Filed 8–17–09; 8:45 am] FR 17868), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0583. The approval expires on July 31, 2012. A copy of the supporting statement for this information collection is available on the Internet at https://www.reginfo.gov/ public/do/PRAMain. Dated: August 11, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E9–19784 Filed 8–17–09; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration BILLING CODE 4160–01–S [Docket No. FDA–2009–N–0336] DEPARTMENT OF HEALTH AND HUMAN SERVICES Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2010; Correction AGENCY: Food and Drug Administration Food and Drug Administration, HHS. [Docket No. FDA–2008–N–0657] ACTION: Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Recommendations for Early Food Safety Evaluation of New NonPesticidal Proteins Produced by New Plant Varieties Intended for Food Use SUMMARY: The Food and Drug Administration is correcting a notice entitled that appeared in the Federal Register of August 3, 2009 (74 FR 38429). The document announced the Fiscal Year 2010 fee rates for the Animal Drug User Fee Act. The document was published with a typographical error. This document corrects that error. FOR FURTHER INFORMATION CONTACT: David Miller, Office of Financial Management (HFA–100), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3917. SUPPLEMENTARY INFORMATION: In FR Doc. E9–18459, appearing on page 38429 in the Federal Register of Monday, August 3, 2009, the following correction is made: 1. On page 38429, in the third column, in the first sentence of the last paragraph under Background, ‘‘$209,400’’ is corrected to read ‘‘$290,400’’. AGENCY: Food and Drug Administration, HHS. jlentini on DSKJ8SOYB1PROD with NOTICES ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ‘‘Recommendations for Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use’’ has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of Information Management (HFA–710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, Daniel.Gittleson@fda.hhs.gov 301–796– 5156. SUPPLEMENTARY INFORMATION: In the Federal Register of April 17, 2009 (74 VerDate Nov<24>2008 16:30 Aug 17, 2009 Jkt 217001 Notice; correction. 41711 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel ZGM1–GDB–X–C1. Date: September 8, 2009. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Natcher Building, Room 3AN18, 45 Center Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: John J. Laffan, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18J, Bethesda, MD 20892, 301–594–2773. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: August 10, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–19624 Filed 8–17–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2009–N–0247] Dated: August 12, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E9–19779 Filed 8–17–09; 8:45 am] Food and Drug Administration Transparency Task Force; Reopening of Comment Period BILLING CODE 4160–01–S HHS. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 AGENCY: E:\FR\FM\18AUN1.SGM Food and Drug Administration, 18AUN1 41712 Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices jlentini on DSKJ8SOYB1PROD with NOTICES ACTION: Notice; reopening of comment period. SUMMARY: The Food and Drug Administration (FDA) is reopening until November 6, 2009, the comment period for the notice of public meeting and request for comments that appeared in the Federal Register of June 3, 2009 (74 FR 26712). In the notice of public meeting and request for comments, FDA’s Transparency Task Force requested comments on ways in which FDA can make useful and understandable information about FDA activities and decision making more readily available to the public. The agency is taking this action because the agency is planning a second public meeting this fall and is reopening the comment period to allow interested persons additional time to submit comments. DATES: Submit written or electronic comments by November 6, 2009. ADDRESSES: Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to https:// www.regulations.gov. All such comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Afia Asamoah, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, rm. 2208, Silver Spring, MD 20993, 301–796– 4625, FAX: 301–847–3531, e-mail: Afia.Asamoah@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of June 3, 2009 (74 FR 26712), FDA published a notice of public meeting and request for comments on ways in which FDA can make useful and understandable information about FDA activities and decisionmaking more readily available to the public, in a manner compatible with the agency’s goal of protecting confidential information, as appropriate. Interested persons were given until August 7, 2009, to submit comments. The agency is planning to hold a second meeting in the fall of 2009 about these issues and is reopening the comment period until November 6, 2009. FDA has also established an online blog at https:// fdatransparencyblog.fda.gov in which interested persons may provide feedback on specific topics. The blog is expected to run through November 2009. Interested persons may submit written or electronic comments to the Division of Dockets Management (see VerDate Nov<24>2008 16:30 Aug 17, 2009 Jkt 217001 ADDRESSES). Submit a single copy of electronic comments to https:// www.reguations.gov or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: August 12, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E9–19778 Filed 8–17–09; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Board of Scientific Counselors, National Center for Public Health Informatics (BSC, NCPHI) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee: Time and Date: 8:30 a.m.–5 p.m., September 2, 2009. Place: Hyatt Regency, 265 Peachtree Street NE., Atlanta, Georgia, 30303 Tel: (404) 577–1234, Fax: (404) 588–4137. Maps & Directions This meeting will also be teleconferenced: Toll Free Number: (866) 713–5586, Participant’s pass code 4624038. Status: Open to the public, limited only by the space available. Purpose: The committee shall advise the Secretary, HHS, and the Director, CDC, concerning strategies and goals for the programs and research within the national centers; shall conduct peerreview of scientific programs; and monitor the overall strategic direction and focus of the national centers. The board, after conducting its periodic reviews, shall submit a written description of the results of the review and its recommendations to the Director, CDC. The board shall perform second-level peer review of applications for grants-in-aid for research and research training activities, cooperative agreements, and research contract proposals relating to the broad areas within the national center. Matters to be Discussed: The board will discuss BSC, NCPHI-related PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 matters, including an update on NCPHI Programs and other BSC-related activities. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Dr. Scott McNabb, National Center for Public Health Informatics, CDC, 1600 Clifton Road, NE., Mailstop E–78, Atlanta, Georgia 30333, Telephone (404) 498–6427, Fax (404) 498–6235. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substance and Disease Registry. Dated: August 10, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–19754 Filed 8–17–09; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory General Medical Sciences Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory General Medical Sciences Council. Date: September 10–11, 2009. Closed: September 10, 2009, 8:30 a.m. to 5 p.m. E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 74, Number 158 (Tuesday, August 18, 2009)]
[Notices]
[Pages 41711-41712]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19778]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0247]


Food and Drug Administration Transparency Task Force; Reopening 
of Comment Period

AGENCY: Food and Drug Administration, HHS.

[[Page 41712]]


ACTION: Notice; reopening of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is reopening until 
November 6, 2009, the comment period for the notice of public meeting 
and request for comments that appeared in the Federal Register of June 
3, 2009 (74 FR 26712). In the notice of public meeting and request for 
comments, FDA's Transparency Task Force requested comments on ways in 
which FDA can make useful and understandable information about FDA 
activities and decision making more readily available to the public. 
The agency is taking this action because the agency is planning a 
second public meeting this fall and is reopening the comment period to 
allow interested persons additional time to submit comments.

DATES: Submit written or electronic comments by November 6, 2009.

ADDRESSES: Submit written comments to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
rm. 1061, Rockville, MD 20852. Submit electronic comments to https://www.regulations.gov. All such comments should be identified with the 
docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Afia Asamoah, Office of the 
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 1, rm. 2208, Silver Spring, MD 20993, 301-796-4625, FAX: 301-847-
3531, e-mail: Afia.Asamoah@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of June 3, 2009 (74 
FR 26712), FDA published a notice of public meeting and request for 
comments on ways in which FDA can make useful and understandable 
information about FDA activities and decisionmaking more readily 
available to the public, in a manner compatible with the agency's goal 
of protecting confidential information, as appropriate. Interested 
persons were given until August 7, 2009, to submit comments. The agency 
is planning to hold a second meeting in the fall of 2009 about these 
issues and is reopening the comment period until November 6, 2009. FDA 
has also established an online blog at https://fdatransparencyblog.fda.gov in which interested persons may provide 
feedback on specific topics. The blog is expected to run through 
November 2009.
    Interested persons may submit written or electronic comments to the 
Division of Dockets Management (see ADDRESSES). Submit a single copy of 
electronic comments to https://www.reguations.gov or two paper copies of 
any mailed comments, except that individuals may submit one paper copy. 
Comments are to be identified with the docket number found in brackets 
in the heading of this document. Received comments may be seen in the 
Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.

    Dated: August 12, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-19778 Filed 8-17-09; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.